Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).
Funding by Fiscal Year
NIH fiscal year (Oct–Sep)
$3.3M
FY22
$1.1M
FY23
$1.1M
FY24
$3.3M
FY25
By Funding Mechanism
R01
8
F30
1
F31
1
R21
1
Funding Gap Analysis
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Dengue Hemorrhagic Fever. Strongest funded area: Translational / Drug Development. Largest gap: Biomarker / Diagnostics.
Biomarker / DiagnosticsPublished, Not NIH-Funded
12 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for Dengue hemorrhagic fever. Existing research activity suggests this may be a viable area for grant applications.
Clinical ResearchPublished, Not NIH-Funded
7 publications in Clinical Trial Publication but no NIH-funded grants found in Clinical Research for Dengue hemorrhagic fever. Existing research activity suggests this may be a viable area for grant applications.
Adjacent Research(3 grants)
These grants mention Dengue Hemorrhagic Fever as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
Other(3)
OtherU01Active
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk
Harris, Eva·UNIVERSITY OF CALIFORNIA BERKELEY·BERKELEY, CA
